298 related articles for article (PubMed ID: 30687633)
1. ALK Inhibitors in the Treatment of ALK Positive NSCLC.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Front Oncol; 2018; 8():557. PubMed ID: 30687633
[No Abstract] [Full Text] [Related]
2. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
4. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract][Full Text] [Related]
5. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
Yu Y; Zhu F; Zhang W; Lu S
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683354
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
8. Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Beardslee T; Lawson J
J Adv Pract Oncol; 2018; 9(1):94-101. PubMed ID: 30564472
[TBL] [Abstract][Full Text] [Related]
9. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
11. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
Front Oncol; 2021; 11():754768. PubMed ID: 34820326
[TBL] [Abstract][Full Text] [Related]
15. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S
J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132
[TBL] [Abstract][Full Text] [Related]
16. Alectinib for treating patients with metastatic
Samacá-Samacá D; Prieto-Pinto L; Peréz AY; Valderrama C; Hernández F
Lung Cancer Manag; 2023 Jun; 12(2):LMT59. PubMed ID: 37287941
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
18. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
19. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
20. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]